During a median follow-up of 2.5 years, 1.6 per cent of patients who received atorvastatin
and 2.4 per cent of patients receiving placebo experienced cardiovascular death, heart attack, stroke, transient ischemic attack, or any arterial revascularisation.
The first-order derivative overlaid spectra of atorvastatin
calcium and fenofibrate denoted that there was no zero crossing point for atorvastatin
calcium for quantification of fenofibrate (Figure 2).
Yamakawa et al reported a significant increase in glycated hemoglobin (HbA1c) in patients with diabetes receiving Atorvastatin
treatment for 3 months, whereas only a minimal change in HbA1c in patients receiving Pitavastatin14.
Cell viability and cytotoxic effects caused by atorvastatin
were determined by a WST-1 assay.
Different statins have varied propensities for causing self-limited myopathy, with atorvastatin
and simvastatin associated with higher rates of myopathy than rosuvastatin; however, there is no established association between specific statins and the occurrence of SINAM [7, 8].
PubMed database was used to search for publications of interest using as keywords "atorvastatin
AND diabetes." Eligible studies were primary studies of every design (observational studies, cross-sectional, cohort, case studies, case series, clinical trials, etc.) published in English until 30/ 04/2015 (date of last search).
used as an adjuvant therapy with currently existing standard therapy (topical betamethasone) in patients having mild to moderate plaque type psoriasis reduces disease severity and cardiovascular risks.
Oral administration of atorvastatin
(10 mg) led to decline in CFFF from the baseline score taken before intake of test drug.
Analysis of the proliferation assays shows that both atorvastatin
solution and atorvastatin-medicated dentifrice reduced the percentage of CD4+ T cell proliferation compared with control and dentifrice without atorvastatin
Our case highlights a serious drug induced myotoxicity from high dose atorvastatin
, two and a half months after instituting ticagrelor and continuing with amlodipine.
At the same time, the patient remained on her therapeutic regimen, which included atorvastatin
20 mg once daily.
Forty-five rats were randomly allocated to the following five groups (n = 9 per group): (1) control group (dehydration + furosemide, without CM administration); (2) CIAKI group; (3) CI-AKI + rosuvastatin group (10 mg/kg, AstraZeneca Pharmaceutical Co., Ltd., UK); (4) CI-AKI + simvastatin group (80 mg/kg, Merck & Co., Inc., USA); and (5) CI-AKI + atorvastatin
group (20 mg/kg, Pfizer Pharmaceuticals Ltd., USA).